I n 2018, rectal cancer was the eighth most common cancer in the world (1). Survival rates have increased in the past decade mainly because of total mesorectal excision surgery and neoadjuvant treatment, when indicated. However, patients with metastatic disease remain a challenge. Norwegian patients with metastatic rectal cancer have a 5-year survival rate of 18.3% for men and 20.6% for women (2). To enable a more adapted treatment, there is a need to assess individual tumor characteristics that can be used to identify patients who will respond poorly to conventional therapies and have higher risk of metastatic disease. Anatomic MRI is important for staging rectal cancer. Many studies have also examined the predictive and prognostic value of functional MRI, especially dynamic contrast-enhanced (DCE) MRI that can be analyzed qualitatively, semiquantitatively, or quantitatively. Recently, Dijkhoff et al (3) demonstrated value for DCE MRI in rectal cancer, despite large variability in the performed studies, and called for larger studies to be undertaken.